Literature DB >> 29280693

Epistaxis 2016: national audit of management.

.   

Abstract

BACKGROUND: Epistaxis is a common condition that can be associated with significant morbidity, and it places a considerable burden on our healthcare system. This national audit of management sought to assess current practice against newly created consensus recommendations and to expand our current evidence base.
METHODS: The management of epistaxis patients who met the inclusion criteria, at 113 registered sites across the UK, was compared with audit standards during a 30-day window. Data were further utilised for explorative analysis.
RESULTS: Data for 1826 cases were uploaded to the database, representing 94 per cent of all cases that met the inclusion criteria at participating sites. Sixty-two per cent of patients were successfully treated by ENT clinicians within 24 hours. The 30-day recurrent presentation rate across the dataset was 13.9 per cent. Significant event analysis revealed an all-cause 30-day mortality rate of 3.4 per cent.
CONCLUSION: Audit findings demonstrate a varying alignment with consensus guidance, with explorative analysis countering some previously well-established tenets of management.

Entities:  

Keywords:  Cautery; Epistaxis; Hematology; Surgery; Symptom Assessment

Mesh:

Year:  2017        PMID: 29280693     DOI: 10.1017/S002221511700202X

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.

Authors:  Petar Stankovic; Robert Georgiew; Cornelius Frommelt; Sabine Hammel; Jan Wittlinger; Stephan Hoch; Danilo Obradovic; Nikolaos Dagres; Thomas Wilhelm
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

2.  ENT audit and research in the era of trainee collaboratives.

Authors:  Matthew E Smith; John Hardman; Matthew Ellis; Richard J Williams
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-26       Impact factor: 2.503

3.  Tranexamic acid for patients with nasal haemorrhage (epistaxis).

Authors:  Jonathan Joseph; Pablo Martinez-Devesa; Jenny Bellorini; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2018-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.